Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
Animal Medicine (1) ·
Phantastica (1) ·
potent non-selective)]] (1) ·
weak μ-agonist with serotonin/norepinephrine reuptake inhibition)]] (1) ·
[[:Category:Analgesics|Analgesic]] (2) ·
[[:Category:NSAIDs|Non-steroidal anti-inflammatory (NSAID (1) ·
[[:Category:Opioid analgesics|Opioid analgesic (atypical (1) ·
[[:Category:Schedule IV controlled substances|Schedule IV controlled substance]] (1)
'"`UNIQ--vote-00000006-QINU`"' (1) ·
'"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"' (1) ·
'"`UNIQ--vote-0000001F-QINU`"', '"`UNIQ--vote-00000020-QINU`"', '"`UNIQ--vote-00000021-QINU`"', '"`UNIQ--vote-00000022-QINU`"', '"`UNIQ--vote-00000023-QINU`"', '"`UNIQ--vote-00000024-QINU`"', '"`UNIQ--vote-00000025-QINU`"' (1)
None (1) ·
Acute gout: 50 mg PO TID until symptom relief, then taper; maximum 200 mg/day for 3-5 days. Rheumatoid arthritis / osteoarthritis: 25-50 mg PO BID-TID. Patent ductus arteriosus: 0.2 mg/kg IV, then 0.1-0.2 mg/kg every 12-24 hours for 2 doses (1) ·
IR: 25-50 mg PO every 4-6 hours as needed, titrate as tolerated. ER: 100 mg PO once daily, titrate by 100 mg every 5 days (1)
Capsules 25, 50 mg; ER capsules 75 mg; oral suspension 25 mg/5 mL; suppositories 50 mg; injection 1 mg/vial (PDA closure) (1) ·
IR tablets 50 mg; ER tablets 100, 200, 300 mg (Ultram ER, ConZip); oral solution 5 mg/mL; combination products with acetaminophen (Ultracet) (1) ·
Parotid-gland venom expressed onto a glass plate, dried into a shellac-like resin, vaporized and inhaled (1)
None (1) ·
Avoid from 20 weeks gestation onward per FDA's 2020 expanded NSAID warning; contraindicated from 30 weeks (risk of premature ductus arteriosus closure, which is paradoxically the basis of the neonatal PDA-closure indication)'"`UNIQ--ref-00000028-QINU`"' (1) ·
Chronic third-trimester exposure produces neonatal opioid withdrawal syndrome and respiratory depression at delivery.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
5-MeO-DMT is Schedule I in US (since 2011); the toad itself is protected in several southwestern states (1) ·
[[USLegal:Prescription only|Rx-only]] in US (1) ·
[[USLegal:Schedule IV|Schedule IV controlled substance]] in US (federally scheduled 2014); some states schedule higher'"`UNIQ--ref-0000001F-QINU`"' (1)
Showing below up to 3 results in range #1 to #3.


